In a study of participants in the British Society for Rheumatology Biologics Register for Ankylosing Spondylitis (BSRBR-AS), 51.3% of those with axial spondyloarthritis (axSpA) commencing treatment with TNF inhibitors reported a positive response, a lower proportion than that reported in clinical trials (61.7%). Compared with the real-world BSRBR-AS cohort, participants in the clinical trials were more likely to be male, HLA-B27 positive and younger (by approximately 6 years). Disease activity was similar in both groups but the BSRBR-AS participants reported poorer function prior to commencing treatment.
References
Original article
Jones, G. T. et al. Real-world evidence of TNF inhibition in axial spondyloarthritis: can we generalise the results from clinical trials? Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2019-216841 (2020)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Onuora, S. Anti-TNF response falls short in real-world cohort. Nat Rev Rheumatol 16, 350 (2020). https://doi.org/10.1038/s41584-020-0439-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-020-0439-8
